论文部分内容阅读
目的探讨米非司酮对子宫内膜异位症(EM)患者腹腔镜术后复发及血清中IL-12的影响。方法治疗组口服米非司酮6个月,对照组为空白对照,两组采用ELISA法检测治疗前后血清中IL-12水平。结果复发率治疗组与对照组比较,差异有统计学意义(P﹤0.01)。两组血清IL-12术后5d、6月、1年均有所上升,治疗组1年、6月分别与术后5d比较,1年与6月比较,差异均有统计学意义(P﹤0.01)。对照组1年、6月分别与术后5d比较,1年与6月比较,差异均无统计学意义(P﹥0.05)。1年、6月治疗组与对照组分别比较,差异均有统计学意义(P﹤0.01)。结论米非司酮对EM患者腹腔镜术后复发有抑制作用。IL-12在EM发病中起重要作用,检测其含量变化对于该病的复发具有参考意义。
Objective To investigate the effect of mifepristone on the recurrence of laparoscopic surgery and serum IL-12 in patients with endometriosis (EM). Methods The patients in the treatment group were given mifepristone for 6 months. The control group was blank control group. The levels of IL-12 in serum before and after treatment were measured by ELISA in both groups. Results The recurrence rate in the treatment group and the control group, the difference was statistically significant (P <0.01). The levels of IL-12 in serum of both groups increased at 5 days, 6 months and 1 year after operation. The difference was statistically significant between 1-year and 6-month postoperatively in the treatment group and 5 days postoperatively and 1-year and 6-month postoperatively respectively (P < 0.01). The control group 1 year, 6 months respectively compared with 5 days after operation, 1 year and June, the difference was not statistically significant (P> 0.05). The differences between the treatment group and the control group in 1 year and 6 months were statistically significant (P <0.01). Conclusion Mifepristone can inhibit the relapse after laparoscopic surgery in patients with EM. IL-12 plays an important role in the pathogenesis of EM. To detect the change of its content has reference value for the relapse of the disease.